{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:38:34Z","timestamp":1773074314822,"version":"3.50.1"},"reference-count":62,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Agency for Medical Research and Development","award":["24am0521010"],"award-info":[{"award-number":["24am0521010"]}]},{"name":"Japan Agency for Medical Research and Development","award":["JP23ama121008"],"award-info":[{"award-number":["JP23ama121008"]}]},{"name":"Japan Agency for Medical Research and Development","award":["JP23am0401013"],"award-info":[{"award-number":["JP23am0401013"]}]},{"name":"Japan Agency for Medical Research and Development","award":["JP23bm1123027"],"award-info":[{"award-number":["JP23bm1123027"]}]},{"name":"Japan Agency for Medical Research and Development","award":["JP23ck0106730"],"award-info":[{"award-number":["JP23ck0106730"]}]},{"name":"Japan Agency for Medical Research and Development","award":["22K06995"],"award-info":[{"award-number":["22K06995"]}]},{"name":"Japan Agency for Medical Research and Development","award":["21K20789"],"award-info":[{"award-number":["21K20789"]}]},{"name":"Japan Agency for Medical Research and Development","award":["21K07168"],"award-info":[{"award-number":["21K07168"]}]},{"name":"Japan Agency for Medical Research and Development","award":["22K07224"],"award-info":[{"award-number":["22K07224"]}]},{"name":"Japan Society for the Promotion of Science","award":["24am0521010"],"award-info":[{"award-number":["24am0521010"]}]},{"name":"Japan Society for the Promotion of Science","award":["JP23ama121008"],"award-info":[{"award-number":["JP23ama121008"]}]},{"name":"Japan Society for the Promotion of Science","award":["JP23am0401013"],"award-info":[{"award-number":["JP23am0401013"]}]},{"name":"Japan Society for the Promotion of Science","award":["JP23bm1123027"],"award-info":[{"award-number":["JP23bm1123027"]}]},{"name":"Japan Society for the Promotion of Science","award":["JP23ck0106730"],"award-info":[{"award-number":["JP23ck0106730"]}]},{"name":"Japan Society for the Promotion of Science","award":["22K06995"],"award-info":[{"award-number":["22K06995"]}]},{"name":"Japan Society for the Promotion of Science","award":["21K20789"],"award-info":[{"award-number":["21K20789"]}]},{"name":"Japan Society for the Promotion of Science","award":["21K07168"],"award-info":[{"award-number":["21K07168"]}]},{"name":"Japan Society for the Promotion of Science","award":["22K07224"],"award-info":[{"award-number":["22K07224"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Podoplanin (PDPN) overexpression is associated with poor clinical outcomes in various tumors. PDPN is involved in malignant tumor progression by promoting invasiveness and metastasis. Therefore, PDPN is considered a promising target of monoclonal antibody (mAb)-based therapy. Because PDPN also plays an essential role in normal cells such as kidney podocytes, cancer specificity is required to reduce adverse effects on normal cells. We developed a cancer-specific mAb (CasMab) against PDPN, PMab-117 (rat IgM, kappa), by immunizing rats with PDPN-overexpressed glioblastoma cells. The recombinant mouse IgG2a-type PMab-117 (PMab-117-mG2a) reacted with the PDPN-positive tumor PC-10 and LN319 cells but not with PDPN-knockout LN319 cells in flow cytometry. PMab-117-mG2a did not react with normal kidney podocytes and normal epithelial cells from the lung bronchus, mammary gland, and corneal. In contrast, one of the non-CasMabs against PDPN, NZ-1, showed high reactivity to PDPN in both tumor and normal cells. Moreover, PMab-117-mG2a exerted antibody-dependent cellular cytotoxicity in the presence of effector splenocytes. In the human tumor xenograft models, PMab-117-mG2a exhibited potent antitumor effects. These results indicated that PMab-117-mG2a could be applied to antibody-based therapy against PDPN-expressing human tumors while reducing the adverse effects.<\/jats:p>","DOI":"10.3390\/cells13221833","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T06:27:39Z","timestamp":1730874459000},"page":"1833","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Cancer-Specific Anti-Podoplanin Monoclonal Antibody, PMab-117-mG2a Exerts Antitumor Activities in Human Tumor Xenograft Models"],"prefix":"10.3390","volume":"13","author":[{"given":"Tomohiro","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5132","authenticated-orcid":false,"given":"Hiroyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9039-4474","authenticated-orcid":false,"given":"Tomokazu","family":"Ohishi","sequence":"additional","affiliation":[{"name":"Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, 18-24 Miyamoto, Numazu-shi 410-0301, Shizuoka, Japan"},{"name":"Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4158-9208","authenticated-orcid":false,"given":"Mika K.","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-8201","authenticated-orcid":false,"given":"Yukinari","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nri2763","article-title":"Therapeutic antibodies: Past, present and future","volume":"10","author":"Leavy","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies\u2014A role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2165\/00003495-200767170-00008","article-title":"Cetuximab: A review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer","volume":"67","author":"Blick","year":"2007","journal-title":"Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of Therapeutic Antitumor Monoclonal Antibodies","volume":"81","author":"Tsao","year":"2021","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2012.44.9694","article-title":"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"31","author":"Hurvitz","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Suzuki, H., Kaneko, M.K., and Kato, Y. (2022). Roles of Podoplanin in Malignant Progression of Tumor. Cells, 11.","DOI":"10.20944\/preprints202201.0280.v1"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Quintanilla, M., Montero-Montero, L., Renart, J., and Mart\u00edn-Villar, E. (2019). Podoplanin in Inflammation and Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030707"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.oraloncology.2018.01.011","article-title":"Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target","volume":"78","author":"Retzbach","year":"2018","journal-title":"Oral. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.18632\/oncotarget.6598","article-title":"Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis","volume":"7","author":"Sekiguchi","year":"2016","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"38838","DOI":"10.1074\/jbc.M407210200","article-title":"Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha\/Podoplanin) molecules expressed in Chinese hamster ovary cells","volume":"279","author":"Kaneko","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Braun, A., Anders, H.J., Gudermann, T., and Mammadova-Bach, E. (2021). Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.665534"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/jb\/mvs108","article-title":"The impact of Aggrus\/podoplanin on platelet aggregation and tumour metastasis","volume":"152","author":"Fujita","year":"2012","journal-title":"J. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-017-9672-2","article-title":"Platelet-activating factor podoplanin: From discovery to drug development","volume":"36","author":"Takemoto","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ccr.2006.03.010","article-title":"Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton","volume":"9","author":"Wicki","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1242\/jcs.03218","article-title":"Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition","volume":"119","author":"Castel","year":"2006","journal-title":"J. Cell Sci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Pecora, A., Laprise, J., Dahmene, M., and Laurin, M. (2021). Skin Cancers and the Contribution of Rho GTPase Signaling Networks to Their Progression. Cancers, 13.","DOI":"10.3390\/cancers13174362"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1042\/BST20211071","article-title":"Role of Rho GTPases in stem cell regulation","volume":"49","author":"Zhang","year":"2021","journal-title":"Biochem. Soc. Trans."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41568-021-00332-6","article-title":"Linking EMT programmes to normal and neoplastic epithelial stem cells","volume":"21","author":"Lambert","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Astarita, J.L., Acton, S.E., and Turley, S.J. (2012). Podoplanin: Emerging functions in development, the immune system, and cancer. Front. Immunol., 3.","DOI":"10.3389\/fimmu.2012.00283"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.yexcr.2015.04.019","article-title":"PKA and CDK5 can phosphorylate specific serines on the intracellular domain of podoplanin (PDPN) to inhibit cell motility","volume":"335","author":"Krishnan","year":"2015","journal-title":"Exp. Cell Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/cas.13580","article-title":"Podoplanin: An emerging cancer biomarker and therapeutic target","volume":"109","author":"Krishnan","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1038\/s41467-023-42571-1","article-title":"A circular RNA activated by TGF\u03b2 promotes tumor metastasis through enhancing IGF2BP3-mediated PDPN mRNA stability","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102976","DOI":"10.1016\/j.isci.2021.102976","article-title":"Podoplanin drives dedifferentiation and amoeboid invasion of melanoma","volume":"24","author":"George","year":"2021","journal-title":"iScience"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"26089","DOI":"10.1074\/jbc.M113.497685","article-title":"CD147, CD44, and the epidermal growth factor receptor (EGFR) signaling pathway cooperate to regulate breast epithelial cell invasiveness","volume":"288","author":"Grass","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_28","first-page":"514","article-title":"Podoplanin promotes the invasion of oral squamous cell carcinoma in coordination with MT1-MMP and Rho GTPases","volume":"5","author":"Li","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1242\/jcs.171959","article-title":"The CD44s splice isoform is a central mediator for invadopodia activity","volume":"129","author":"Zhao","year":"2016","journal-title":"J. Cell Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s43018-020-0082-y","article-title":"Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4(+) and PDPN(+) CAFs to clinical outcome","volume":"1","author":"Friedman","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00595-017-1559-x","article-title":"Expression of podoplanin in stromal fibroblasts plays a pivotal role in the prognosis of patients with pancreatic cancer","volume":"48","author":"Hirayama","year":"2018","journal-title":"Surg. Today"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1845038","DOI":"10.1080\/2162402X.2020.1845038","article-title":"Tumor-infiltrating podoplanin(+) cells in gastric cancer: Clinical outcomes and association with immune contexture","volume":"9","author":"Liu","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/1945892420930976","article-title":"Expression of Podoplanin in Sinonasal Squamous Cell Carcinoma and Its Clinical Significance","volume":"34","author":"Wang","year":"2020","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Asif, P.J., Longobardi, C., Hahne, M., and Medema, J.P. (2021). The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis. Cancers, 13.","DOI":"10.3390\/cancers13184720"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1476-4598-12-168","article-title":"Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas","volume":"12","author":"Shindo","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/j.1365-2559.2011.04060.x","article-title":"Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma","volume":"59","author":"Pula","year":"2011","journal-title":"Histopathology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1158\/0008-5472.CAN-10-3228","article-title":"Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: Podoplanin in fibroblast functions for tumor progression","volume":"71","author":"Hoshino","year":"2011","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2018.03.006","article-title":"Analysis of cancer-associated fibroblasts and the epithelial-mesenchymal transition in cutaneous basal cell carcinoma, squamous cell carcinoma, and malignant melanoma","volume":"79","author":"Sasaki","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2020.12.020","article-title":"Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma","volume":"153","author":"Suzuki","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1158\/1078-0432.CCR-14-0846","article-title":"Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation","volume":"21","author":"Yoshida","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lungcan.2018.10.021","article-title":"Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma","volume":"126","author":"Sakai","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1038\/s41467-022-32782-3","article-title":"Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors","volume":"13","author":"Rivas","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kato, Y., and Kaneko, M.K. (2014). A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci. Rep., 4.","DOI":"10.1038\/srep05924"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/mab.2017.0001","article-title":"LpMab-23: A Cancer-Specific Monoclonal Antibody Against Human Podoplanin","volume":"36","author":"Yamada","year":"2017","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Suzuki, H., Ohishi, T., Kaneko, M.K., and Kato, Y. (2023). A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models. Cancers, 15.","DOI":"10.20944\/preprints202308.1756.v1"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/cam4.1049","article-title":"Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity","volume":"6","author":"Kaneko","year":"2017","journal-title":"Cancer Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.bbrc.2006.08.171","article-title":"Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain","volume":"349","author":"Kato","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kaneko, M.K., Suzuki, H., Ohishi, T., Nakamura, T., Tanaka, T., and Kato, Y. (2024). A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031941"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1111\/cas.14891","article-title":"Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents","volume":"112","author":"Ukaji","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/mab.2017.0014","article-title":"ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity","volume":"36","author":"Kaneko","year":"2017","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","article-title":"Dynamics and specificities of T cells in cancer immunotherapy","volume":"23","author":"Oliveira","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/2326-6066.CIR-15-0060","article-title":"CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains","volume":"4","author":"Shiina","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.omto.2022.07.006","article-title":"Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47\u0394 combination therapy against glioblastoma","volume":"26","author":"Chalise","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Waseda, M., and Kaneko, S. (2020). Podoplanin as an Attractive Target of CAR T Cell Therapy. Cells, 9.","DOI":"10.3390\/cells9091971"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.str.2024.02.007","article-title":"Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies","volume":"32","author":"Arimori","year":"2024","journal-title":"Structure"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/mab.2023.0033","article-title":"Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H(2)Mab-250\/H(2)CasMab-2 for Breast Cancers","volume":"43","author":"Kaneko","year":"2024","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Suzuki, H., Ohishi, T., Tanaka, T., Kaneko, M.K., and Kato, Y. (2024). Anti-HER2 Cancer-Specific mAb, H(2)Mab-250-hG(1), Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202407.0864.v1"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.21.00917","article-title":"Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","article-title":"A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus","volume":"12","author":"Tijink","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.oraloncology.2007.10.009","article-title":"Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma","volume":"44","author":"Riechelmann","year":"2008","journal-title":"Oral. Oncol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/22\/1833\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:27:12Z","timestamp":1760113632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/22\/1833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":62,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["cells13221833"],"URL":"https:\/\/doi.org\/10.3390\/cells13221833","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]}}}